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Background 
Infection with the severe acute respiratory coronavirus 2 (SARS-CoV-2) has led to a worldwide pandemic 
with coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, overwhelming healthcare 
systems globally. Preliminary reports suggest a high incidence of infection and mortality with SARS-CoV-
2 in patients receiving kidney replacement therapy (KRT). The aims of this study are to report 
characteristics, rates and outcomes of all patients affected by infection with SARS-CoV-2 undergoing KRT 
in Scotland. 
Methods 
Study design was an observational cohort study. Data were linked between the Scottish Renal Registry, 
Health Protection Scotland and the Scottish Intensive Care Society Audit Group national data sets using 
a unique patient identifier (Community Health Index (CHI)) for each individual by the Public Health and 
Intelligence unit of Public Health, Scotland. Descriptive statistics and survival analyses were performed. 
Results  
During the period 1st March 2020 to 31st May 2020, 110 patients receiving KRT tested positive for SARS-
CoV-2 amounting to 2% of the prevalent KRT population. Of those affected, 86 were receiving 
haemodialysis or peritoneal dialysis and 24 had a renal transplant. Patients who tested positive were 
older and more likely to reside in more deprived postcodes. Mortality was high at 26.7% in the dialysis 
patients and 29.2% in the transplant patients.  
Conclusion 
The rate of detected SARS-CoV-2 in people receiving KRT in Scotland was relatively low but with a high 
mortality for those demonstrating infection.  Although impossible to confirm, it appears that the 
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measures taken within dialysis units coupled with the national shielding policy, have been effective in 
protecting this population from infection.   
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Background 
Infection with the severe acute respiratory coronavirus 2 (SARS-CoV-2) has led to a worldwide pandemic 
with COVID-19, the disease caused by SARS-CoV-2, overwhelming healthcare systems globally (1). The 
clinical course of the disease varies significantly from asymptomatic disease to multi-organ failure and 
death(2). Patients receiving kidney replacement therapy (KRT) are a vulnerable population as those 
receiving dialysis are usually older with significant co-morbidity, have impaired immune responses (3) 
and require regular attendance at a healthcare facility which further increases their risk of exposure. 
Patients who have a kidney transplant are presumed to be at high risk due to their obligate 
immunosuppressive medications. There have been a number of published recommendations on how to 
mitigate spread of SARS-CoV-2 in dialysis units (4-8). There is, however, a lack of data regarding clinical 
course and outcome in patients receiving KRT following infection with SARS-CoV-2. Furthermore, early 
reports suggest that case fatality in dialysis patients if infected is high with reports suggesting fatality in 
the order of 5-20% compared to 1-2% in patients not requiring KRT (9-11). Patients requiring KRT often 
have multiple comorbid conditions which are widely documented as increasing the risk of death from 
COVID-19 such as older age, chronic conditions such as diabetes mellitus and hypertension (12, 13) but 
may be at additional risk due to the relatively impaired immune response associated with kidney failure.    
The first case of SARS-CoV-2 infection in Scotland was confirmed on 1st March 2020, although 
subsequent data suggest that the virus had been in circulation for weeks prior to this (14). On 24th 
March, as part of the Scottish Government response to the pandemic, certain groups of patients were 
identified as the most vulnerable to developing severe illness and advised to “shield” meaning they were 
advised to remain at home and minimise all non-essential contact with other members of their 
household. This “shielded” category included kidney transplant recipients (KTR) from the outset but 
Scottish (and United Kingdom) government advice was not applied to dialysis patients until 28th April 
2020. However, most renal units commenced implementation of PPE protocols prior to government 
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advice. Delivering care to these patients whilst minimising risk of exposure and preventing transmission 
of infection to these vulnerable patient groups posed significant challenges to renal units across the 
country.  
The aims of this study are to report characteristics, rates and outcomes of all patients affected by 
infection with SARS-CoV-2 undergoing chronic KRT including KTRs in Scotland. 
Methods 
Data Sources 
Study design was an observation cohort study. The following national data sets were linked using a 
unique patient identifier (Community Health Index (CHI)) for each individual by Public Health and 
Intelligence unit of Public Health, Scotland. The Scottish Renal Registry is a national registry of all 
patients receiving KRT for end stage renal disease (ESRD) in Scotland (haemodialysis, peritoneal dialysis 
and transplant). It was established in 1991 with data backfilled to 1960 from European Renal 
Association-European Dialysis and Transplant Association (ERA-EDTA) with the first patient dialysed for 
ESRD in Scotland in 1960. The Scottish Renal Registry has 100% unit and patient coverage. Data held by 
the registry include patient demographics including historical postcodes (for calculating Scottish Index of 
Multiple Deprivation), full KRT history (for ESRD), date and cause of death (using ERA-EDTA codes), 
primary renal diagnosis (using ERA-EDTA codes) and monthly linkage with National Health Service Blood 
and Transplant (NHS BT) for transplant status. The primary renal diagnosis groupings used in the 
analyses is described in the Scottish Renal Registry website (15).  The Scottish Government provide 
online calculators allowing use of patient postcode to generate divisions of socioeconomic deprivation, 
the Scottish Index of Multiple Deprivation (SIMD)(16). Using patient postcode, deprivation quintiles 
were calculated and categorized into most deprived quintiles with 1 corresponding to most deprived 
and 5 as least deprived. Data on testing for COVID-19 were obtained from Health Protection Scotland 
6 
 
with date of test and result reported. Data on admission to intensive care units were obtained from the 
Scottish Intensive Care Society Audit Group (SICSAG). The Scottish Intensive Care Society Audit Group 
(SICSAG) has maintained a national database of patients admitted to adult general Intensive Care Units 
(ICU) in Scotland since 1995(17). Detailed information is produced on the management of critically ill or 
injured patients. All general intensive care units (ICU) and combined ICU/high dependency units (HDU) 
collect data.  During this period, there was no limitation of access to ICU admission for patients with 
comorbid conditions, with patients admitted to ICU if clinicians felt it was clinically appropriate.  
Testing for SARS-CoV-2 was carried out by real-time polymerase chain reaction (RT-PCR) on a combined 
nasal and pharyngeal throat swab only in symptomatic patients or endotracheal aspirate for those 
ventilated in ICU. If a patient has been tested multiple times, the date of the first positive or first 
negative test was used. If a patient has tested positive, then subsequently tested negative they would 
only appear in the positive cohort. 
 
Statistical Analysis 
Data were linked and analysed by a Public Health Intelligence analyst at Public Health Scotland. Baseline 
characteristics were displayed as mean and standard deviation (SD) or median and interquartile range 
(IQR) for continuous variables depending on normality. T-tests and chi-squared tests were utilised to 
examine differences in parameters between those who died and those were still alive as of 31st May 
2020. Categorical variables were displayed as number and percentage. Logistic regression was 
performed with SARS-Cov-2 positivity as a binary outcome. Crude survival was measured at 30 days 
since first SARS-Cov-2 test using Kaplan Meier survival analyses. Cox proportional hazards models were 
performed to examine predictors of death. All analyses were performed using R Studio 3.5.1(18). 
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Results 
Scottish Renal Registry 
The Scottish renal registry collates data from all 9 adult renal units in Scotland and 28 satellite 
haemodialysis units (Figure 1) serving a population of 5.4 million. On 31st May 2020, there were 5475 
prevalent patients in Scotland receiving KRT. Of these, 1983 were on haemodialysis and 206 peritoneal 
dialysis and 3286 with functioning kidney transplants.   
Characteristics of SARS-CoV-2 positive patients 
As of 31st May 2020, 876 patients receiving KRT had been tested for SARS-CoV-2 infection. This 
represents 16% of the total number of 5475 receiving KRT on 31st May 2020. One hundred and ten were 
positive which amounts to 2% of the prevalent KRT population. Of those affected, 86 were receiving 
haemodialysis or peritoneal dialysis and 24 had a renal transplant. Figure 2 shows the distribution of 
those individuals who tested positive for SARS-CoV-2 by geographical location relative to the whole KRT 
population. In keeping with the national figures related to the general population, the majority of 
positive tests were within the central belt of Scotland. Figure 3a shows the number of positive cases by 
week with a peak in positive cases between the 30th of March and 13th of April.  This contrasts with data 
for general population across Scotland where the number of new cases only started to fall during week 
beginning 27th April (Figure 3b).  There were 986 tests performed in 876 patients until the 31st May with 
110 (11.2%) testing positive. The cumulative number tested and the proportion of positive cases over 
time is shown in Figures 4a and b with a sharp increase in testing over the time period examined. 
Characteristics of the kidney replacement population and those who tested positive for SARS-CoV-2 are 
shown in Table 1. Mean age of those tested positive was 64.3 years old (SD 14.4) with a primary renal 
diagnosis of diabetes in 33.7% and median dialysis vintage of 4 years (IQR 1-8 years). Of the 24 patients 
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who had a functioning kidney transplant when tested positive for SARS-CoV-2, the majority of the 
transplants (n=14) were performed over 10 years ago with 8% (n=2) cases recorded had a transplant less 
than 2 years ago.  65% of those who tested positive lived in the most deprived areas (SIMD 1 or 2). 98 of 
110 who tested positive were of white ethnicity. We do not have data on the ethnicity of the entire KRT 
population. Using logistic regression, increasing age at time of infection OR 1.038 (95%CI 1.023- 1.053), 
p< 0.001 and social deprivation OR 0.778 (95% CI 0.673-0.899), p=0.001 (with every quintile increase in 
in SIMD) were predictors of testing positive for all those on KRT on 31 May 2020 registered on the SRR. 
 
Patient Outcomes 
As of the 31st May 2020, 30 (28.2%) of the patients who tested positive for SARS-CoV-2 infection died. 
Twenty three (26.7%) of the 86 patients treated with haemodialysis or peritoneal dialysis who tested 
positive died. Seven (29.2%) of the 24 transplant patients who tested positive died.  Mean age of death 
was higher in those who died compared with those who were still alive as of 31st May 2020 (69 years (SD 
11.6) vs. 62 years (SD 8.5), p=0.0182). There was no difference in median dialysis vintage of those who 
died compared with those who were still alive as of 31st May 2020: 4 years (IQR 1-12 years) vs 4 years 
(IQR 1-7 years, p=0.34). One third of patients who died had a primary renal diagnosis of diabetic 
nephropathy. Figure 5 shows the total number of deaths in the KRT therapy population in Scotland from 
1st January 2020 to 31st May 2020 with those who had COVID-19 identified as a primary cause of death 
on the death certificate. Figure 6 shows the number of deaths from 1st January to 31st May each year 
from 2017 to 2020. Deaths in 2020 not related to COVID-19 are also shown.  Both figures 5 and 6 
demonstrate an increase in deaths occurring in April compared with other months.  Figure 5 in particular 
highlights that a large proportion (35%) of the deaths occurring in April were related to COVID-19. Crude 
thirty day survival is shown in Figures 7a and 7b. There was 91% (95% CI 89- 94) 30 day survival in those 
to tested negative compared with 71% (95% CI 63 -80) 30 day survival in those who tested positive. 
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Increasing age was associated with mortality in cox proportional hazards model with an increase of 
hazard ratios for death of 1.028 (95% CI 1.001 to 1.055, p=0.038) for every year of age. 
 
Intensive Care Admission 
During the period from 1st March 2020 to 31st May 2020 there were a total of 118 patients registered 
on the SRR who were admitted to an ICU/HDU in Scotland. Of these 13 (13%) patients had tested 
positive for SARS-CoV-2 infection. 92.3% of those with SARS-CoV-2 were discharged alive from ICU 
compared with 94.1% who were not tested/tested negative. However, of those who were discharged 
alive from ICU/HDU 41.6% of those with a positive SARS-CoV-2 test died within 7 days of being 
discharged compared to 6.94% of those who did not have a positive test result. Details of ICU/ HDU 
admission are shown in Table 2. 
 
Discussion 
As of May 31st 2020, SARS-CoV-2 was detected in 2% of the prevalent Scottish KRT population (3.9% of 
the prevalent dialysis population and 0.7% of the prevalent transplant population). Mortality was high at 
26.7% in the dialysis patients and 29.2% in the transplant patients.  Patients who tested positive were 
more likely to be older and from more deprived postcodes. Increasing age was associated with 
mortality.  
During the early stages of the pandemic, advice about personal protective equipment (PPE) was subject 
to a number of changes mainly in response to guidance issued by UK government for use of PPE in the 
healthcare environment. On 2nd April 2020, the UK and Scottish governments issued new PPE guidelines 
for patients and staff in secondary care and these in turn informed the UK Renal Association 
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recommendations for PPE in dialysis units (8, 19).   The guidance has largely remained unchanged since 
and essentially advocates that staff use face masks (one per session) and single use aprons and gloves 
with all patients, including those where COVID was not suspected.  After discussion with local 
microbiology/infectious disease/infection control teams, most units implemented these changes in renal 
dialysis units very quickly with all units following this guidance by 6th April 2020.  Two units adopted this 
approach before the government advice with the earliest adoption of PPE on 13th March 2020. 
All dialysis patients now wear a mask for travelling into dialysis and during the session. Patients are 
given a mask to use for next session. Patients are advised to minimise time spent eating or drinking i.e. 
time with mask off.  Waiting areas are a potential challenge as in some units these are very small and 
cannot facilitate adequate social distancing. Approaches to address this includes staggering start times 
for dialysis and asking patients to wait in their transport vehicle until the staff are ready to commence 
their dialysis session.   All patients have individual transport except a few cases where following an 
adequate risk assessment, two patients share an ambulance but wear masks. Individualised transport 
has only been possible whilst there is reduced demand from other specialties which have put non-
essential services on hold or at significant cost to the units by providing single occupancy taxi for 
transport.  Most units have, or are actively making plans for, the time when individual transport is no 
longer available or manageable.  All units measure patient temperature on arrival. The threshold for 
action varies between temperature of 37.8o and 38.0o degrees with the exception of one satellite unit 
which has a threshold of 37.0o. Once reached, this threshold triggers testing for SARS-COV2 and dialysis 
in isolation. All units have taken measures to minimise visits to hospital for people with a functioning 
transplant.  Clinical records are reviewed in advance of clinics.  Unless a face-to-face consultation is 
considered necessary, alternative options have included telephone consultations, blood tests only and 
increased time between clinics. Phone consultations are provided mostly by medical staff but some 
units include transplant nurse specialists. Bloods have been taken in a variety of settings including newly 
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set up ‘bloods only’ clinics, bespoke mobile phlebotomy service, existing community hubs or in 
coordination with primary care.   
There is currently a lack of data on how SARS-CoV-2 affects patients receiving haemodialysis. Early 
reports from Wuhan suggested a milder disease in these patients (20). However, more recent reports 
are suggesting worse outcomes. The Lombardy and Brescia regions of Italy were severely affected by 
COVID-19. An observational study from 4 dialysis centres in the Brescia region of Italy showed that 95 
(15%) of 643 haemodialysis patients tested positive for COVID-19 with 27 (29%) of these dying (21). A 
further observational study from a haemodialysis centre in Spain found that 36 patients out of 282 
patients tested positive for COVID-19 and 11 (30.5%) of these patients subsequently died. Dialysis 
vintage was associated with mortality in this cohort of patients (22). Similarly, a study of 59 consecutive 
patients testing positive from Columbia University in the United States found a mortality rate of 31% (18 
patients)(23). A report from the COVID-19 registry of the Spanish Society of Nephrology reported a 
mortality of 23% in 868 patients with SARS-CoV-2 infection. Mortality was associated with increasing age 
in this cohort(24). A study from a single urban centre in the United Kingdom showed much higher rates 
of transmission with over 20% of their haemodialysis patients affected within 6 weeks of detection of 
their first case (25). Similar mortality rates was demonstrated in this series with 20.3% patients dying 
during follow up, again with increasing age being associated with higher likelihood of mortality. The 
outcomes we report in kidney transplant recipients with 29.2% of those with COVID-19 dying is similar 
to that reported in New York(26). The number of patients in our cohort who required intensive care is 
perhaps lower than might be expected. However, within renal units, detection of SARS-COV2 triggered 
treatment escalation planning. This included discussion with patients about appropriate and realistic 
ceilings of treatment. As a result the number of people referred to ICU will have been reduced. 
In the general population, a number of comorbid conditions such as diabetes, hypertension and obesity 
have consistently been linked to increased risk of death with COVID-19 (12). In patients requiring KRT, it 
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is clear that the risk attributable to requirement for KRT is such a strong risk factor for death that it is 
challenging to identify subgroups of dialysis or kidney transplant recipients at highest risk.  
SARS-CoV-2 has affected a relatively small proportion of the KRT patients in Scotland. However, 
mortality was high in those affected and COVID-19 has been associated with excess mortality in the KRT 
population of Scotland during this period compared to equivalent periods during previous years. Renal 
unit staff and transport services have worked hard to mitigate and contain transmission within the 
individual dialysis and satellite units. The subsequent drop in new cases by the third week of April 
suggests that these measures coupled with shielding were effective. It is not possible to say with 
absolute certainty but the experience in a large dialysis unit in London has led to similar conclusions 
(25).   Infection control measures are likely to have been beneficial in reducing transmission associated 
with dialysis treatment, either related to transport with other patients, or during treatment itself. 
However, it is not possible to dissociate the reduction in number of cases of SARS-CoV-2 in the KRT 
population from the fall observed in the general population in response to measures encompassed by 
‘lockdown’ including closure of schools and non-essential shops, increased hand hygiene and social 
distancing. However, as the incidence of new SARS-CoV-2 infections specifically in patients on KRT fell 
prior to any fall in the incidence of SARS-CoV-2 in Scotland (Figure 3), it is plausible that the combination 
of measures specific to this high risk group had efficacy in driving down new infections, rather than to 
simply assume that falling infection in KRT patients reflected reducing community transmission of SARS-
CoV-2. It is worth noting that highest numbers of SARS-CoV-2 infection was observed in patients residing 
in areas of highest socioeconomic deprivation. Although the numbers of infections do not necessarily 
track to outcomes, most UK and Scotland data demonstrate that infection rates and deaths with SARS-
CoV-2 are higher in areas of socioeconomic deprivation (27).  
A strength of our study is that we have comprehensive coverage of all patients receiving KRT in Scotland 
with linkage to Health Protection Scotland which holds data on all testing for SARS-CoV-2 performed in 
13 
 
Scotland. However, limitations of our study are that we did not have data on hospitalisations, co-
morbidities, immunosuppression regimes, acute kidney injury or smoking status. Fortunately, our 
numbers were small. However, this limits our ability to draw conclusions from our analyses.  Only 
symptomatic patients were tested, so we cannot comment on the asymptomatic rate of SARS-CoV-2 
infection, this may have led to lower case ascertainment in the population of patients with kidney 
transplants. However, unlike in the wider UK population, testing was performed liberally, and to the 
best of our knowledge in all symptomatic patients requiring dialysis and in those without symptoms but 
who presented with fever. 
Conclusion 
In summary, we demonstrate that 2% of the KRT population had a positive test for SARS-CoV-2 during 
the period of study. The incidence of positive tests fell following instigation of infection control 
measures. Mortality is high and it is unclear if any of the therapies demonstrated to improve outcomes 
in patients with COVID-19 such as dexamethasone or remdesivir will have efficacy in patients requiring 
KRT. Patients requiring dialysis were excluded from recent remdesivir trials (28). It is likely that in the 
absence of specific therapy, and high mortality, heightened vigilance of the risk of SARS-CoV-2 infection, 
infection control measures including use of PPE for both staff and patients, will be required for the long 
term to mitigate the risk of SARS-CoV-2 in this vulnerable patient group. This may come at a cost of 
increasing social isolation and more limited social interaction between other patients, health care 
workers and wider society. Moreover, the economic cost of providing additional transport for individual 
patients travelling to dialysis, more dedicated nursing staff and segregated dialysis bays, as well as for 
additional PPE will add substantially to the existing financial burden of KRT to healthcare systems. 
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   Dialysis Transplant 
  
COVID-19 + 
n=86 
Total on HD & PD 
n=2184 
COVID-19 + 
n=24 
Total Transplant 
n=3277 
    n (%) n (%) n (%) n (%) 
Sex 
Female 39 (45) 879 (40) 11 (46) 1318 (40) 
Male 47 (55) 1305 (60) 13 (54) 1959 (60) 
Age Group 
20-44 10 (12) 244 (11) 4 (17) 774 (24) 
45-64 25 (29) 829 (38) 12 (50) 1745 (53) 
65-74 24 (28) 599 (27) 5 (21) 612 (19) 
75+ 27 (31) 512 (23) 3 (13) 146 (4) 
Primary Renal 
Diagnosis 
Glomerulonephritis 14 (16) 374 (17) 3 (13) 851 (26) 
Interstitial 20 (23) 464 (21) 12 (50) 1275 (39) 
Multisystem 15 (17) 489 (22) 3 (13) 386 (12) 
Diabetes 29 (34) 569 (26) 3 (13) 386 (12) 
Unknown 8 (9) 288 (13) 3 (13) 379 (12) 
*Dialysis Vintage 
< 1 year 20 (23) 444 (20) 0 (0) 310 (9) 
1-2 years 14 (16) 349 (16) 2 (8) 314 (10) 
2 - 3 years 8 (9) 293 (13) 1 (4) 339 (10) 
<= 5 years 22 (26) 468 (21) 3 (13) 698 (21) 
<=10 years 11 (13) 243 (11) 4 (17) 701 (21) 
> 10 years 11 (13) 301 (14) 14 (58) 88 (27) 
SIMD 1=most deprived 32 (37) 634 (29) 7 (29) 715 (22) 
2 24 (28) 503 (23) 5 (21) 698 (21) 
3 10 (12) 417 (19) 4 (17) 631 (19) 
4 13 (15) 356 (16) 5 (21) 646 (20) 
5=least deprived 7 (8) 274 (13) 3 (13) 587 (18) 
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Patients with missing data (n=14) not included in total for analysis purposes - none of which were 
COVID-19 +     
*Dialysis vintage for those on transplant is taken from the date of the transplant, those on dialysis is 
their time on KRT.   
     
Table 1: Descriptive characteristics of all prevalent patients undergoing KRT in Scotland on 31st May 2020 
 
 
 
 
  COVID-19 Positive 
COVID-19 
Negative Not Tested 
Total of SRR 
Patients 
Number of patients with ICU/HDU stay   13 77 28 118 
Median Length of Stay  6.0 4.0 3.0 4.0 
Average Advanced Ventilation Days  2.6 0.7 0.1 0.8 
Average Non Invasive Ventilation Days   0.5 0.2 0.0 0.2 
Average Cardio Support Days  1.4 0.7 0.2 0.7 
Average Renal Support Days  2.8 2.1 0.5 1.8 
 
Table 2: Details of ICU/ HDU admission 
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 Legends to Figures 
Figure 1: Dialysis Locations in Scotland (own figure) 
ARI Aberdeen Royal Infirmary, XH Crosshouse Hospital, DGRI Dumfries and Galloway Royal Infirmary, GLAS Glasgow Royal Infirmary, MONK Monklands 
Hospital, NINE Ninewells Hospital Dundee, RAIG Raigmore Hospital Inverness, RIE Royal Infirmary of Edinburgh, VHK Victoria Hospital Kirkcaldy. 
Figure 2: Geographical output of SARS-CoV-2 in KRT patients up to 31 May 2020 (own figure) 
Figure 3a: Number of patients* on KRT who tested positive for SARS-CoV-2  
*If a patient has been tested multiple times, the date of the first positive or first negative test was used. If a patient has tested positive, then subsequently 
tested negative they would only appear in the positive cohort. 
Figure 3b: Number of patients in Scotland who tested positive for SARS-CoV-2  
Figure 4a: Cumulative number of SRR patients* on KRT with a SARS-CoV-2 test 
Figure 4b: Cumulative number of SRR patients* on KRT with a SARS-CoV-2 test split by modality  
Figure 4c: Cumulative number of patients in Scotland with a SARS-CoV-2 test 
Figure 5: Number of Deaths in KRT population per calendar month  
*For all those patients who tested positive for SARS-CoV-2 – all had SARS-CoV-2 as Cause of Death on death certificate. 
Figure 6: Number of deaths in KRT population – comparison over multiple years 
*This lines shows the number of deaths after removing those cases where SARS-CoV-2 was the Cause of Death. 
Figure 7a: Survival at 30 days from first SARS-CoV-2 test 
*Log Rank Test for KM is p<0.001 
Figure 7b: Survival at 30 days from first SARS-CoV-2 Test split by modality at time of test result 
 
